RIO DE JANEIRO, BRAZIL - CanSino Biologics Inc will start testing its coronavirus vaccine candidate in late-stage human trials in Argentina and Chile, the co-founder of the Chinese pharmaceutical company said on Saturday, November 21st.
The candidate Ad5-nCoV, which goes by the trade name Convidecia, uses a harmless common cold virus to carry genetic information of coronavirus’ protein to elicit immune responses, has already begun Phase III trials in Pakistan, Russia and Mexico.
CanSino will begin interim analysis of the late-stage trial results when 50 infection cases are found, said Zhu Tao, who is also the company . . .